文献速递肝病消化道肿瘤与早癌

荟萃分析:肝细胞癌监测的利用现状

Meta-Analysis: Utilisation of Hepatocellular Carcinoma Surveillance.
PubMed 文献 · Aliment Pharmacol Ther · 2025-10-12

结果显示任何监测的合并利用率为54.45%,而半年一次监测仅8.76%,且利用率未随时间改善。

要点

  • 高危人群任何肝癌监测合并利用率仅54.45%。
  • 按指南半年一次监测的利用率不足10%。
  • 肝癌监测利用率未随时间推移而改善。

核心结论

  • 不足10%的患者接受了推荐的半年一次超声监测。
  • 肝癌监测利用率低,需提高认识和协作。

研究设计与样本

  • 纳入报告肝硬化或慢性乙肝患者接受超声肝癌监测比例的研究。
  • 采用广义线性混合模型进行比例荟萃分析。

主要发现

  • 高危人群任何肝癌监测合并利用率54.45%(95%CI 37.77-70.19,n=21项研究)。
  • 半年一次监测利用率8.76%(95%CI 2.46-26.79,n=7项研究)。
  • 肝硬化患者任何监测利用率53.37%(95%CI 33.72-72.03,n=15项研究)。
  • 慢性乙肝患者任何监测利用率66.43%(95%CI 42.74-83.99,n=12项研究)。
  • 肝硬化患者半年一次监测利用率10.20%(95%CI 1.92-39.71),慢性乙肝患者12.96%(95%CI 0.02-99.09)。

关键数值与推荐

  • 40,497例确诊肝癌患者中,既往接受筛查或经监测诊断的比例为36.07%(95%CI 28.30-44.63,n=27项研究)。
  • 监测利用率未随时间改善。

临床怎么用

  • 应加强高危人群肝癌监测的宣教与实施。
  • 需促进照护提供者与卫生政策制定者协作以提高监测利用率。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Major society guidelines recommend hepatocellular carcinoma (HCC) surveillance every 6 months with hepatic ultrasound. HCC surveillance is associated with early detection and improved survival but is underutilised. We aim to provide an updated assessment of HCC surveillance utilisation. METHODS: Ovid MEDLINE and Embase were searched from inception until 30 November 2023 to identify studies reporting the proportion of people with either cirrhosis or chronic hepatitis B who underwent ultrasound-based HCC surveillance. The primary objective was to determine the utilisation of HCC surveillance. A meta-analysis of proportions was conducted using a generalised linear mixed model. RESULTS: Forty-eight articles (1,275,349 individuals) met inclusion criteria. In at-risk individuals (cirrhosis or chronic hepatitis B), pooled utilisation of any HCC surveillance (n = 21 studies) was 54.45% (95% CI: 37.77-70.19), and utilisation of biannual surveillance (n = 7 studies) was 8.76% (95% CI: 2.46-26.79). Utilisation of any HCC surveillance was 53.37% (95% CI: 33.72-72.03) in patients with cirrhosis (n = 15 studies) and 66.43% (95% CI: 42.74-83.99) in patients with chronic hepatitis B (n = 12 studies), while utilisation of biannual surveillance was 10.20% (95% CI: 1.92-39.71) and 12.96% (95% CI: 0.02-99.09) respectively. Utilisation of surveillance did not improve over time. Pooled analysis of 40,497 individuals diagnosed with HCC (n = 27 studies) determined that the proportion of patients who had undergone prior screening or been diagnosed by surveillance was 36.07% (95% CI: 28.30-44.63). CONCLUSIONS: Less than 10% of patients received the recommended biannual ultrasound scans for surveillance. These findings are concerning and call for greater awareness and collaboration between care providers and healthcare policymakers to improve surveillance utilisation.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Tang NSY, Gunalan S, Ong CEY, et al. Meta-Analysis: Utilisation of Hepatocellular Carcinoma Surveillance. Aliment Pharmacol Ther. 2025. PMID: 41077883. doi:10.1111/apt.70403

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。